Entero Healthcare Solutions Limited ENTERO NSEPHARMA

Healthcare · Medical Distribution · India

https://www.enterohealthcare.com

Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.

Market & Price

Market Cap

₹5,203.90 Cr

Current Price

₹1,195.80

High / Low (52W)

₹1,354.40 / ₹949.20

Beta

-0.65

Valuation

Stock P/E

45.24

Industry PE

37.60

Forward P/E

21.69

PEG Ratio

Book Value

₹388.26

Price to Book

3.08

P/S

0.79

EV/EBITDA

21.25

Dividend Yield

Profitability & Returns

ROCE

11.61%

ROE

8.28%

ROA

4.42%

Profit Margin

1.75%

Op Margin

3.73%

EPS (Latest Qtr)

₹6.43

EPS (TTM)

₹26.43

Balance Sheet & Liquidity

Debt/Equity

0.39

Quick Ratio

0.95

Current Ratio

1.58

Debt

₹677.15 Cr

Total Assets

₹3,600.26 Cr

Current Assets

₹2,508.44 Cr

Working Capital

₹920.87 Cr

Ownership

Promoter Holding

66.97%

Chg in Prom Hold

FII / Inst Holding

11.89%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

₹5,650.21 Cr

Total Revenue (TTM)

₹6,591.21 Cr

EBITDA

₹265.95 Cr

Free Cash Flow

₹69.68 Cr

Operating Cash Flow

₹96.20 Cr

Shares Outstanding

₹4.35 Cr

Gross Margin

10.32%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

26.02%

Profit 5Y

365.14%

Revenue (YoY)

42.60%

Earnings (YoY)

9.10%

PROS

Compounding revenue at 26.0% over 5 years.
Profit CAGR of 365.1% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ENTERO Entero Healthcare Solutions Limited NSEPHARMA	1,195.80	45.24	₹5,203.90 Cr	-	11.61%	8.28%	26.02%	365.14%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	1,339.06 Cr	1,403.82 Cr	1,570.95 Cr	1,706.52 Cr	1,909.93 Cr
Cost of Revenue	-	-	1,208.29 Cr	1,264.25 Cr	1,410.15 Cr	1,533.93 Cr	1,702.51 Cr
Gross Profit	-	-	130.77 Cr	139.57 Cr	160.80 Cr	172.59 Cr	207.42 Cr
Operating Expenses	-	-	90.35 Cr	98.37 Cr	108.57 Cr	114.62 Cr	136.17 Cr
Operating Income	-	-	40.42 Cr	41.20 Cr	52.23 Cr	57.98 Cr	71.25 Cr
EBITDA	-	-	56.21 Cr	55.90 Cr	66.86 Cr	64.21 Cr	90.05 Cr
Interest Expense	-	-	10.49 Cr	10.66 Cr	12.40 Cr	14.01 Cr	17.31 Cr
Pretax Income	-	-	37.23 Cr	36.36 Cr	44.62 Cr	40.40 Cr	57.95 Cr
Tax Provision	-	-	5.80 Cr	6.13 Cr	8.03 Cr	6.52 Cr	12.82 Cr
Net Income	-	-	25.69 Cr	27.80 Cr	31.60 Cr	27.63 Cr	28.01 Cr
Diluted EPS	5.42	-	5.90	6.38	7.25	6.34	6.43

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	3,293.14 Cr	3,888.16 Cr	5,095.78 Cr	6,591.21 Cr
Cost of Revenue	-	3,031.86 Cr	3,570.35 Cr	4,609.47 Cr	5,910.83 Cr
Gross Profit	-	261.28 Cr	317.81 Cr	486.31 Cr	680.38 Cr
Operating Expenses	-	221.51 Cr	230.98 Cr	345.45 Cr	457.72 Cr
Operating Income	-	39.77 Cr	86.83 Cr	140.86 Cr	222.66 Cr
EBITDA	-	64.95 Cr	121.05 Cr	211.05 Cr	277.01 Cr
Interest Expense	-	44.40 Cr	60.48 Cr	41.62 Cr	54.38 Cr
Pretax Income	-	-3.69 Cr	35.55 Cr	138.74 Cr	179.34 Cr
Tax Provision	-	7.42 Cr	-4.24 Cr	31.30 Cr	33.50 Cr
Net Income	-	-11.56 Cr	39.11 Cr	94.82 Cr	115.04 Cr
Diluted EPS	-6.88	-2.66	10.81	21.76	-

Compounded Sales Growth

5 Years:	26.02%
1 Year:	42.60%

Compounded Profit Growth

5 Years:	365.14%
1 Year:	9.10%

Stock Price Performance

1 Year:	-7.06%
6 Months:	+12.59%
3 Months:	+10.80%
1 Month:	+0.03%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	1,308.73 Cr	2,344.97 Cr	2,702.51 Cr	3,600.26 Cr
Current Assets	-	1,023.17 Cr	2,010.97 Cr	2,075.71 Cr	2,508.44 Cr
Cash & Equivalents	-	25.36 Cr	147.65 Cr	229.28 Cr	146.88 Cr
Inventory	-	341.63 Cr	421.15 Cr	659.78 Cr	841.68 Cr
Receivables	-	514.88 Cr	615.40 Cr	830.36 Cr	1,212.44 Cr
Total Liabilities	-	711.07 Cr	703.59 Cr	932.16 Cr	1,847.72 Cr
Current Liabilities	-	623.96 Cr	601.94 Cr	845.02 Cr	1,587.57 Cr
Long Term Debt	-	31.07 Cr	45.54 Cr	0	122.56 Cr
Total Debt	-	437.76 Cr	337.97 Cr	385.23 Cr	677.15 Cr
Total Equity	-	595.03 Cr	1,638.06 Cr	1,724.14 Cr	1,688.61 Cr
Shares Outstanding	-	4.35 Cr	4.35 Cr	4.35 Cr	4.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	-45.31 Cr	-36.61 Cr	-76.86 Cr	96.20 Cr
Investing Cash Flow	-	-48.59 Cr	-705.12 Cr	219.80 Cr	-303.06 Cr
Financing Cash Flow	-	72.76 Cr	862.94 Cr	-73.66 Cr	123.66 Cr
Capital Expenditure	-	-5.52 Cr	-5.42 Cr	-11.31 Cr	-67.54 Cr
Free Cash Flow	-	-50.83 Cr	-42.03 Cr	-88.18 Cr	28.66 Cr
Net Change in Cash	-	-21.15 Cr	121.21 Cr	69.28 Cr	-83.20 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	7.9%	8.2%	9.5%	10.3%
Operating Margin %	-	1.2%	2.2%	2.8%	3.4%
Net Margin %	-	-0.4%	1.0%	1.9%	1.7%
ROE %	-	-1.9%	2.4%	5.5%	6.8%
ROCE %	-	5.8%	5.0%	7.6%	11.1%

Shareholding Pattern

Insiders

66.97%

Institutions

11.89%

Public Float

35.99%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENTERO

No recent headlines available.

ENTERO · Healthcare